专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140205592A1 Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors 审中-公开
公开(公告)号：US20140205592A1
公开(公告)日：2014-07-24
申请号：US14221370
申请日：2014-03-21
申请人： Guenther ADOLF , Pilar GARIN-CHESA , Ulrich HIRT
发明人： Guenther ADOLF , Pilar GARIN-CHESA , Ulrich HIRT
IPC分类号： G01N33/574 , C12Q1/68
CPC分类号： G01N33/57492 , C12Q1/6886 , G01N33/57484 , G01N33/57496 , G01N2333/705 , G01N2333/91205 , G01N2800/52
摘要： The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor. In a further aspect, the present invention relates to a PTK2 inhibitor for use in the treatment of a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2. The present invention also provides a method of screening for a therapeutically effective PTK2 inhibitor comprising the steps of (a) providing cancer cells or a cancer cell line which are characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being even more preferred); (b) contacting the cancer cell or the cancer cell line of (a) with a PTK2 inhibitor; and (c) evaluating whether the PTK2 inhibitor negatively affects the cancer cell/cancer cell lines. In a further aspect, the present invention relates to a method for stratifying cancer patients that are susceptible to treatment with a PTK2 inhibitor, comprising determining the E-cadherin IRS score in a cancer sample of said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 (i.e. 2, 1, or 0) indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The present invention also relates to a pharmaceutical package comprising a PTK2 inhibitor, and (a) instructions and/or an imprint indicating that said PTK2 inhibitor is to be used for the treatment of patients which suffer from a cancer which is characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being more preferred); and/or (b) instructions and/or an imprint indicating that said patient is to be stratified by a method of the present invention; and/or (c) means to carry out a method as defined herein.

2. 发明申请

US20050244413A1 Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents 审中-公开
标题翻译：使用细胞毒性CD44抗体免疫缀合物和化学治疗剂治疗癌症的组合物和方法
公开(公告)号：US20050244413A1
公开(公告)日：2005-11-03
申请号：US11172320
申请日：2005-06-30
申请人： Guenther Adolf , Anke Baum , Karl-Heinz Heider
发明人： Guenther Adolf , Anke Baum , Karl-Heinz Heider
IPC分类号： A61K31/337 , A61K39/395 , A61K45/06 , A61K47/48 , C07K16/46
CPC分类号： A61K31/337 , A61K39/395 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2300/00
摘要： The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates contain maytansinoids as cytotoxic compounds, and preferred chemotherapeutic agents are taxanes, epothilones, and vinca alcaloids.
摘要翻译：本发明涉及CD44特异性抗体与细胞毒性化合物和化学治疗剂的缀合物在癌症治疗中的组合使用，包含这些化合物和/或化学治疗剂的药物组合物和癌症治疗方法。优选的缀合物含有美登木素生物碱作为细胞毒性化合物，优选的化学治疗剂是紫杉烷类，埃坡霉素和长春花碱。

3. 发明授权

US647190A Pneumatic tire. 失效
公开(公告)号：US647190A
公开(公告)日：1900-04-10
申请号：US1899738707
申请日：1899-11-29
申请人： LINS RICHARD , GUENTHER ADOLF
发明人： LINS RICHARD , GUENTHER ADOLF
CPC分类号： B60C11/02

4. 发明授权

US09274120B2 Stratification of pancreatic and ovarian cancer patients for susceptibility to therapy with PTK2 inhibitors 有权
公开(公告)号：US09274120B2
公开(公告)日：2016-03-01
申请号：US14221370
申请日：2014-03-21
申请人： Guenther Adolf , Pilar Garin-Chesa , Ulrich Hirt
发明人： Guenther Adolf , Pilar Garin-Chesa , Ulrich Hirt
IPC分类号： G01N33/53 , C12Q1/00 , G01N33/574 , C12Q1/68
CPC分类号： G01N33/57492 , C12Q1/6886 , G01N33/57484 , G01N33/57496 , G01N2333/705 , G01N2333/91205 , G01N2800/52
摘要： The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor. In a further aspect, the present invention relates to a PTK2 inhibitor for use in the treatment of a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2. The present invention also provides a method of screening for a therapeutically effective PTK2 inhibitor comprising the steps of (a) providing cancer cells or a cancer cell line which are characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being even more preferred); (b) contacting the cancer cell or the cancer cell line of (a) with a PTK2 inhibitor; and (c) evaluating whether the PTK2 inhibitor negatively affects the cancer cell/cancer cell lines. In a further aspect, the present invention relates to a method for stratifying cancer patients that are susceptible to treatment with a PTK2 inhibitor, comprising determining the E-cadherin IRS score in a cancer sample of said patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 (i.e. 2, 1, or 0) indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The present invention also relates to a pharmaceutical package comprising a PTK2 inhibitor, and (a) instructions and/or an imprint indicating that said PTK2 inhibitor is to be used for the treatment of patients which suffer from a cancer which is characterized by an E-cadherin protein immunoreactivity score of 2, 1, or 0 (1 being preferred and 0 being more preferred); and/or (b) instructions and/or an imprint indicating that said patient is to be stratified by a method of the present invention; and/or (c) means to carry out a method as defined herein.

5. 发明授权

US08568727B2 Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them 有权
标题翻译：对成纤维细胞活化蛋白和含有它们的免疫缀合物的抗体分子
公开(公告)号：US08568727B2
公开(公告)日：2013-10-29
申请号：US12159070
申请日：2006-12-22
申请人： Guenther Adolf , Elinborg Ostermann , Milena Kalat , Karl-Heinz Heider
发明人： Guenther Adolf , Elinborg Ostermann , Milena Kalat , Karl-Heinz Heider
IPC分类号： A61K39/395 , C07K1/107 , C07K16/00
CPC分类号： C07K16/40 , A61K47/6803 , A61K47/6849 , A61K47/6871 , C07K2317/24 , C07K2317/33 , C07K2317/92
摘要： Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.
摘要翻译：抗FAP抗体和免疫偶联物，含有这些缀合物的药物组合物及其在癌症治疗中的应用。

6. 发明申请

US20120244141A1 Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors 审中-公开
标题翻译：癌症患者对PTK2抑制剂治疗易感性的分层
公开(公告)号：US20120244141A1
公开(公告)日：2012-09-27
申请号：US13237833
申请日：2011-09-20
申请人： Guenther ADOLF , Pilar GARIN-CHESA , Ulrich HIRT
发明人： Guenther ADOLF , Pilar GARIN-CHESA , Ulrich HIRT
IPC分类号： A61K39/395 , A61P35/00 , A61K31/713 , A61K31/7105 , G01N21/76 , G01N33/574
CPC分类号： G01N33/57492 , C12Q1/6886 , G01N33/57484 , G01N33/57496 , G01N2333/705 , G01N2333/91205 , G01N2800/52
摘要： A method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The invention further encompasses treatment of a patient with a protein tyrosine kinase 2 (PTK2) inhibitor if it has been so determined that said patient is susceptible to such treatment.
摘要翻译：一种确定癌症患者是否易于用蛋白酪氨酸激酶2（PTK2）抑制剂治疗的方法，包括检测所述癌症患者的癌症样品中E-钙粘蛋白蛋白的表达，其中E-钙粘蛋白蛋白免疫反应性评分（IRS）为0-2表示癌症患者易于用PTK2抑制剂治疗。如果已经确定所述患者易于进行这种治疗，本发明还包括治疗患有蛋白酪氨酸激酶2（PTK2）抑制剂的患者。

7. 发明申请

US20090304718A1 Antibody Molecules Specific for Fibroblast Activation Protein and Immunoconjugates Containing Them 有权
标题翻译：成纤维细胞活化蛋白和含有免疫偶联物的抗体分子
公开(公告)号：US20090304718A1
公开(公告)日：2009-12-10
申请号：US12159070
申请日：2006-12-22
申请人： Guenther Adolf , Elinborg Ostermann , Milena Kalat , Karl-Heinz Heider
发明人： Guenther Adolf , Elinborg Ostermann , Milena Kalat , Karl-Heinz Heider
IPC分类号： A61K39/395 , C07K16/00 , C07K1/107 , A61P35/00 , A61P37/00
CPC分类号： C07K16/40 , A61K47/6803 , A61K47/6849 , A61K47/6871 , C07K2317/24 , C07K2317/33 , C07K2317/92
摘要： Anti-FAP-antibodies and immunoconjugates, pharmaceutical compositions containing such conjugates, and their use in cancer therapy.
摘要翻译：抗FAP抗体和免疫偶联物，含有这些缀合物的药物组合物及其在癌症治疗中的应用。

8. 发明授权

US07361347B2 Cytotoxic CD44 antibody immunoconjugates 有权
标题翻译：细胞毒性CD44抗体免疫缀合物
公开(公告)号：US07361347B2
公开(公告)日：2008-04-22
申请号：US11173969
申请日：2005-07-01
申请人： Guenther Adolf , Erik Patzelt , Marlies Sproll , Karl-Heinz Heider
发明人： Guenther Adolf , Erik Patzelt , Marlies Sproll , Karl-Heinz Heider
IPC分类号： A61K39/395
CPC分类号： A61K47/6849 , A61K47/6803
摘要： The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.
摘要翻译：本发明涉及CD44抗体与细胞毒性化合物的新型缀合物，包含这些化合物的药物组合物及其在肿瘤治疗中的用途。

9. 发明申请

US20050271672A1 Cytotoxic CD44 antibody immunoconjugates 有权
标题翻译：细胞毒性CD44抗体免疫缀合物
公开(公告)号：US20050271672A1
公开(公告)日：2005-12-08
申请号：US11173969
申请日：2005-07-01
申请人： Guenther Adolf , Erik Patzelt , Marlies Sproll , Karl-Heinz Heider
发明人： Guenther Adolf , Erik Patzelt , Marlies Sproll , Karl-Heinz Heider
IPC分类号： A61K47/48 , A61K39/395 , C07K16/46
CPC分类号： A61K47/6849 , A61K47/6803
摘要： The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy.
摘要翻译：本发明涉及CD44抗体与细胞毒性化合物的新型缀合物，包含这些化合物的药物组合物及其在肿瘤治疗中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式